Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, type 2 | List with criteria/condition | Complete | ||
Aubagio | Teriflunomide | Multiple sclerosis, relapsing-remitting | Do not list at the submitted price | Complete | ||
Adempas | Riociguat | Chronic thromboembolic pulmonary hypertension | List with criteria/condition | Complete | ||
Simponi I.V. | Golimumab | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
Tivicay | Dolutegravir | HIV infection | List | Complete | ||
Diacomit | Stiripentol | Dravet Syndrome | List with criteria/condition | Complete | ||
Abilify | Aripiprazole | Depression, Major Depressive Disorder | Do not list | Complete | ||
Breo Ellipta | Fluticasone furoate /vilanterol | Chronic Obstructive Pulmonary Disease (COPD) | List with criteria/condition | Complete | ||
Sovaldi | Sofosbuvir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
Stelara | Ustekinumab | Arthritis, psoriatic | Do not list at the submitted price | Complete |